Delivery Order VA69D17D0031-VA69D17J1004

The U.S. Department of Veterans Affairs (VA), specifically the Veterans Integrated Service Network 22 (VISN 22), awarded a firm-fixed-price purchase order to Myriad Genetics Inc. for $154,938.00 to provide Prolaris genetic testing services. Prolaris is a molecular diagnostic test that measures gene expression levels to assess prostate cancer aggressiveness. This contract is for the VA Long Beach Healthcare System to utilize Myriad's Prolaris testing capabilities on an as-needed basis from...

The Department of Veterans Affairs Veterans Health Administration awarded a firm-fixed-price purchase order contract valued at one hundred thirty-two thousand four hundred fifty-five dollars and ninety-one cents ($132,455.91) to Myriad Genetics Inc. to provide Prolaris testing services in support of prostate cancer diagnostics for the VA Long Beach Healthcare System located in Long Beach, California. The contract calls for the contractor to perform quantitative PCR analysis on prostate biopsy...

This federal contract award with ID HT001417A0029|HT001419F0321 was made by the Defense Health Agency (DHA) to Myriad Genetics Inc., a molecular diagnostic company, for Myriad's Prolaris genetic testing services. The $100,000.00 firm-fixed-price contract is for quantitative PCR analysis and reporting to assess prostate cancer aggressiveness and guide treatment approaches. This appears to be a Blanket Purchase Agreement (BPA) call, with Myriad Genetics having been awarded multiple prior BPA calls...

This federal contract award from the Department of Veterans Affairs (VA) Veterans Health Administration was granted to Myriad Genetic Laboratories Inc., a subsidiary of Myriad Genetics Inc., to provide Prolaris prostate cancer testing services. The firm fixed price contract, valued at $14,994.00, is a Blanket Purchase Agreement (BPA) call to support disease risk stratification and treatment planning for veterans served by the VA's Veterans Integrated Service Network (VISN) 19 in Salt Lake...

This federal contract award to Myriad Genetics Inc. is for a Blanket Purchase Agreement (BPA) call valued at $100,000 to provide genetic testing services related to cancer diagnostics and risk assessment. The contract was awarded by the Defense Health Agency, a component of the Department of Defense, to deliver Myriad's Prolaris quantitative PCR testing on prostate biopsy samples. The Prolaris test helps assess tumor aggressiveness and guide treatment approaches for prostate cancer patients....

This firm-fixed-price purchase order was awarded by the National Institute of Child Health and Human Development (NICHD), a civilian agency within the U.S. Department of Health and Human Services, to Myriad RBM, Inc., a subsidiary of Myriad Genetics, Inc. The $10,157.40 contract is for the provision of Myriad's Prolaris quantitative PCR testing services to assess prostate cancer tumor aggressiveness and guide treatment approaches. No set-aside designation was mentioned. Myriad Genetics, a...

This is a firm fixed price purchase order contract awarded by the U.S. Army Medical Command (MEDCOM) to Propath Services, LLC, a for-profit organization, for the provision of analysis services for inconclusive biopsies. The contract has a ceiling value of $80,000.00 and an ultimate completion date of September 30, 2017. This contract award is not associated with a larger contract vehicle and does not have a set-aside designation. Propath Services, LLC is a nationwide pathology practice that...

Myriad Genetic Laboratories Inc. was awarded a firm fixed price blanket purchase agreement (BPA) call contract valued at $20,467 by the Department of Veterans Affairs Veterans Health Administration (VA VHA) to provide ProLARIS prostate cancer testing services for the VA Salt Lake City Health Care System (SLCVAMC) in Salt Lake City, Utah. As the prime contractor, Myriad Genetic Laboratories will deliver the requested prostate cancer genomic testing to assist the SLCVAMC with disease risk...

This is a firm fixed price purchase order awarded by the Defense Health Agency to Cytopath Biopsy Lab Inc., doing business as Cblpath, for the provision of THROSEQ V.2 MOLECULAR TESTING services. The contract has a completion date of September 30, 2017 and a potential value of $150,000.00. Cblpath is a for-profit organization that provides specialized anatomic pathology and molecular diagnostic laboratory services, primarily focused on cancer screening and diagnosis utilizing next-generation...

The Department of Veterans Affairs Veterans Integrated Service Network 22 awarded a firm fixed-price purchase order valued at $2.31M to Cytopath Biopsy Lab Inc. (doing business as Cblpath) for ThyroSeq molecular diagnostic testing services. Under this contract, Cblpath will provide approximately 225 tests annually to multiple VA healthcare facilities within VISN 22, with interpretive reports to be delivered within 14 days of testing. The ThyroSeq test analyzes genetic mutations in thyroid...